- STAT+: FDA revisits a rare cancer treatment it rejected a few months agoSecret drug pricing deals, a virtual AI cancer clinic, and other biotech news from The ReadoutSTAT · 2mo ago↗ source
- STAT+: OpenAI’s health policy wishlist, CGM news from Dexcom, and moreIn this edition of STAT Health Tech: A health policy blueprint from OpenAI, CGM updates from Dexcom, and push back against whole body scans.STAT · 2mo ago↗ source
- STAT+: FDA to reconsider treatment for rare cancer after its surprise rejectionThe companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.STAT · 2mo ago↗ source